Vericel to Report Fourth-Quarter 2020 Financial Results on February 24, 2021
11 February 2021 - 12:00AM
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies
for the sports medicine and severe burn care markets, today
announced the following webcast and conference call to discuss its
fourth-quarter 2020 financial results and business highlights.
What: |
Vericel Corporation Fourth-Quarter 2020 Earnings Call |
When: |
Wednesday, February 24, 2021
at 8:30am (EST) |
Where: |
http://investors.vcel.com/events-presentations |
How: |
The conference call will be
available live in the Investors section of the Vericel website at
http://investors.vcel.com/events-presentations. Please access
the site at least 15 minutes prior to the scheduled start time in
order to download the required audio software if necessary.
Presentation slides for the conference call will be available on
the webcast and in the Investor Relations section of the Vericel
website. |
To participate in the live call by telephone, please call (877)
312-5881 and reference Vericel Corporation fourth-quarter 2020
earnings call. If calling from outside the U.S., please use the
international phone number (253) 237-1173.
If you are unable to participate in the live call, the webcast
will be available at http://investors.vcel.com/events-presentations
until February 24, 2022. A replay of the call will also be
available until 11:30am (EST) on March 3, 2021 by calling (855)
859-2056, or from outside the U.S. (404) 537-3406. The conference
ID is 4364298.
About Vericel CorporationVericel
is a leader in advanced therapies for the sports medicine and
severe burn care markets. The company markets two cell therapy
products in the United States. MACI® (autologous cultured
chondrocytes on porcine collagen membrane) is an autologous
cellularized scaffold product indicated for the repair of
symptomatic, single or multiple full-thickness cartilage defects of
the knee with or without bone involvement in adults. Epicel®
(cultured epidermal autografts) is a permanent skin replacement for
the treatment of patients with deep dermal or full thickness burns
greater than or equal to 30% of total body surface area. The
company also holds an exclusive license for North American
commercial rights to NexoBrid®, a registration-stage biological
orphan product for debridement of severe thermal burns. For more
information, please visit the company's website at
www.vcel.com.
Epicel® and MACI® are registered trademarks of Vericel
Corporation. NexoBrid® is a registered trademark of MediWound Ltd.
and is used under license to Vericel Corporation. © 2021 Vericel
Corporation. All rights reserved.
Investor Contact: Chad RubinSolebury
Troutcrubin@troutgroup.com +1 646-378-2947
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024